



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/624,193	07/21/2003	Wayne P. Fitzmaurice	60-016511US	7725
22798	7590 01/13/2006		EXAMINER	
QUINE INT	ELLECTUAL PROPE	WOITACH, JOSEPH T		
P O BOX 458			APTIBUT	DARCH MUMBER
ALAMEDA, CA 94501			ART UNIT	PAPER NUMBER
			1632	

DATE MAILED: 01/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	Applicant(s)			
Office Action Summary		10/624,193	FITZMAURICE E	FITZMAURICE ET AL.			
		Examiner	Art Unit				
		Joseph T. Woitach	1632				
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet	with the correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REP CHEVER IS LONGER, FROM THE MAILING Insions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication, or period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by status teply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN. .136(a). In no event, however, may d will apply and will expire SIX (6) Mo tte, cause the application to become	NICATION. a reply be timely filed ONTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).	•			
Status							
1)□	Responsive to communication(s) filed on						
2a)□	-						
3)							
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
4)⊠	Claim(s) 1-15 is/are pending in the application	n.					
-	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)□	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) <u>1-15</u> are subject to restriction and/o	r election requirement.					
Applicat	ion Papers						
9)[The specification is objected to by the Examin	ner.					
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority (under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
	application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Λ + 100 h =	*(a)						
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)							
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper N	o(s)/Mail Date				
	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 or No(s)/Mail Date	8) 5) Notice o 6) Other: _	f Informal Patent Application (PT 	I O-152)			

Art Unit: 1632

DETAILED ACTION

This application filed July 21, 2003, is a continuation of 09/565,616, filed 05/04/2000, now US Patent 6,656,726, which claims benefit of 60/132,697 05/04/1999.

Claims 1-15 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, 6-12, drawn to a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 5 and a viral vector, classified in class 536, subclass 23.1.
- II. Claims 1-3, 6-12, drawn to a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 6 and a viral vector, classified in class 536, subclass 23.1.
- III. Claims 4, 5, drawn to a nucleic acid encoding a 126/183 replicase complex with specific alterations at 1138, 1268,2382 and 3632, classified in class 536, subclass 23.1.
- IV. Claims 13, 14, drawn to a cell transformed with a viral vector containing a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 5, classified in class 435, subclass 325.

Application/Control Number: 10/624,193

Art Unit: 1632

Page 3

- V. Claims 13, 14, drawn to a cell transformed with a viral vector containing a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 6, classified in class 435, subclass 325.
- VI. Claims 13, 14, drawn to a transgenic plant transformed with a viral vector containing a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 5, classified in class 800, subclass 295.
- VII. Claims 13, 14, drawn to a transgenic plant transformed with a viral vector containing a nucleic acid encoding an altered viral movement protein having the amino acid sequence of SEQ ID NO: 6, classified in class 800, subclass 295.

Claims 1 and 7 link(s) inventions I and II, and because of the reference to claim 7groups IV and V, and groups VI and VII. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 1 and 7. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP 804.01.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions encompass two different nucleic acid sequences that encode different proteins.

Inventions IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions encompass two different nucleic acid sequences that encode different proteins generating two different types of cells. While the vector of groups I and II can be used to generate the claimed cell, they have other uses as well for example to generate the protein they encode or for use as a probe.

Inventions VI and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions encompass two different nucleic acid sequences that encode different proteins generating two different types of plants. While the cells of a plant comprise a transgene, the cells of groups IV and V would not be used to generate the plant itself.

Inventions III and I, II, IV-VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the

different inventions encompass multiple unrelated products. More specifically, group III is drawn to a replicates complex, which none of the other groups set forth or require.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, have acquired a separate status in the art because of their recognized divergent subject matter, and the search of one group (for example one specific sequence) would not identify relevant art for any other group, nor would it be complete nor co-extensive with respect to any one group, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/624,193

Art Unit: 1632

Page 6

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

Joe Wortal